178 related articles for article (PubMed ID: 25193858)
1. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Isaacs JT; Dalrymple SL; Rosen DM; Hammers H; Olsson A; Leanderson T
Oncotarget; 2014 Sep; 5(18):8093-106. PubMed ID: 25193858
[TBL] [Abstract][Full Text] [Related]
2. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
Dalrymple SL; Becker RE; Isaacs JT
Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
[TBL] [Abstract][Full Text] [Related]
3. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
Isaacs JT; Antony L; Dalrymple SL; Brennen WN; Gerber S; Hammers H; Wissing M; Kachhap S; Luo J; Xing L; Björk P; Olsson A; Björk A; Leanderson T
Cancer Res; 2013 Feb; 73(4):1386-99. PubMed ID: 23149916
[TBL] [Abstract][Full Text] [Related]
4. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
5. Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer.
Isaacs JT; Dalrymple SL; Antony L; Marc Rosen D; Coleman IM; Nelson PS; Kostova M; Murray IA; Perdew GH; Denmeade SR; Akinboye ES; Brennen WN
Prostate; 2023 Nov; 83(15):1470-1493. PubMed ID: 37559436
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
[TBL] [Abstract][Full Text] [Related]
7. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.
Dalrymple SL; Becker RE; Zhou H; DeWeese TL; Isaacs JT
Prostate; 2012 May; 72(6):638-48. PubMed ID: 21837778
[TBL] [Abstract][Full Text] [Related]
8. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
Olsson A; Björk A; Vallon-Christersson J; Isaacs JT; Leanderson T
Mol Cancer; 2010 May; 9():107. PubMed ID: 20470445
[TBL] [Abstract][Full Text] [Related]
9. [Tasquinimod: How to act on microenvironment in metastatic prostate cancer].
Houédé N; Irani J
Prog Urol; 2015 May; 25(6):298-305. PubMed ID: 25684391
[TBL] [Abstract][Full Text] [Related]
10. The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth.
Deronic A; Tahvili S; Leanderson T; Ivars F
BMC Cancer; 2016 Jul; 16():440. PubMed ID: 27400708
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
Gardner ER; Kelly M; Springman E; Lee KJ; Li H; Moore W; Figg WD
Invest New Drugs; 2012 Feb; 30(1):90-7. PubMed ID: 20820910
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
Armstrong AJ; Häggman M; Stadler WM; Gingrich JR; Assikis V; Polikoff J; Damber JE; Belkoff L; Nordle Ö; Forsberg G; Carducci MA; Pili R
Clin Cancer Res; 2013 Dec; 19(24):6891-901. PubMed ID: 24255071
[TBL] [Abstract][Full Text] [Related]
13. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer.
Isaacs JT
Expert Opin Investig Drugs; 2010 Oct; 19(10):1235-43. PubMed ID: 20836618
[TBL] [Abstract][Full Text] [Related]
14. A review of tasquinimod in the treatment of advanced prostate cancer.
Williamson SC; Hartley AE; Heer R
Drug Des Devel Ther; 2013; 7():167-74. PubMed ID: 23662046
[TBL] [Abstract][Full Text] [Related]
15. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.
Bratt O; Häggman M; Ahlgren G; Nordle O; Björk A; Damber JE
Br J Cancer; 2009 Oct; 101(8):1233-40. PubMed ID: 19755981
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
17. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
Isaacs JT; Pili R; Qian DZ; Dalrymple SL; Garrison JB; Kyprianou N; Björk A; Olsson A; Leanderson T
Prostate; 2006 Dec; 66(16):1768-78. PubMed ID: 16955399
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of tasquinimod on the tumour microenvironment.
Raymond E; Dalgleish A; Damber JE; Smith M; Pili R
Cancer Chemother Pharmacol; 2014 Jan; 73(1):1-8. PubMed ID: 24162378
[TBL] [Abstract][Full Text] [Related]
19. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
20. Tasquinimod: a novel drug in advanced prostate cancer.
Osanto S; van Poppel H; Burggraaf J
Future Oncol; 2013 Sep; 9(9):1271-81. PubMed ID: 23980674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]